Drug costs and out-of-pocket spending in cancer clinical trials

Contemporary Clinical Trials

Volumn 29, Issue 1, 2008, Pages 1-8

  Kilgore, Meredith L ^a   Goldman, Dana P ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b RAND CORPORATION   (United States)

Author keywords

Cancer; Clinical trials; Cost analysis; Prescription drugs

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; ANXIOLYTIC AGENT; ERYTHROPOIETIN; HYPNOTIC AGENT;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA BASE; DRUG COST; DRUG UTILIZATION; FEMALE; HOSPITAL DEPARTMENT; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT PARTICIPATION; PRESCRIPTION;

CLINICAL TRIALS AS TOPIC; DRUG UTILIZATION; FEES, PHARMACEUTICAL; FEMALE; FINANCING, PERSONAL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 36549042901     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2007.04.004     Document Type: Article

References (14)

1. Wagner J.L., Alberts S.R., Sloan J.A., Cha S., Killian J., O'Connell M.J., et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst 91 (1999) 847-853
2. Fireman B.H., Fehrenbacher L., Gruskin E.P., and Ray G.T. Cost of care for patients in cancer clinical trials. J Natl Cancer Inst 92 (2000) 136-142
3. Bennet C.L., Stinson T.J., Vogel V., Robertson L., Leedy D., O'Brien P., et al. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol 18 (2000) 2805-2810
4. Goldman D.P., Berry S.H., McCabe M., Kilgore M.L., Potosky A.L., Schoenbaum M.L., et al. Incremental treatment costs in NCI-sponsored trials. JAMA 289 (2003) 2970-2977
5. Wallack S.S., Thomas C.P., Martin T.C., and Ryan A. Differences in prescription drug use in HMO and self-insured health plans. Med Care Res Rev 64 1 (Feb 2007) 98-116
6. Goldman D.P., Schoenbaum M.L., Potosky A.L., Weeks J.C., Berry S.H., Escarce J.J., et al. Measuring the incremental cost of clinical cancer research. J Clin Oncol 19 (2001) 105-110
7. Goldman D.P., Adams J.L., Berry S.H., Escarce J.J., Kilgore M.L., Lewis J.H., et al. The Cost of cancer treatment study's design and methods. RAND Health Science and Technology Policy Institute (2000)
8. Adams J.L., Goldman D.P., Kilgore M.L., Schonlau M., Schoenbaum M.S., and Escarce J.J. Multi-stage, complex, non-nested samples: sampling patients within and across health care providers. Health Serv Outcomes Res Methodol 4 (2004) 151-167
9. Berk M.L., Schur C.L., and Mohr P. Using survey data to estimate prescription drug costs. Health Aff 9 (1990) 146-156
10. Grootendorst P.V. A comparison of alternative models of prescription drug utilization. Health Econ 4 3 (May-Jun 1995) 183-198
11. Kilgore ML. Effects of Trial Design on Participation and Costs in Clinical Trials With an Examination of Cost Analysis Methods and Data Sources [dissertation] Santa Monica, CA: RAND; 2004.
12. Hirano K, Imbens GW, Ridder G. Efficient Estimation of Average Treatment Effects using the Estimated Propensity Score, NBER Technical Working Paper 251. http://www.nber.org/papers/T0251, accessed 3/19/2007.
13. Rosenbaum P.R., and Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
14. Rosenbaum P.R., and Rubin D.B. Reducing bias in observational studies using sub-classification on the propensity score. JASA 79 (1984) 516-524